Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shTFAM is a short hairpin RNA (shRNA) construct designed to silence the expression of Transcription Factor A, Mitochondrial (TFAM). TFAM is a critical nuclear-encoded protein that regulates the transcription and replication of mitochondrial DNA (mtDNA). In the context of gastrointestinal research, shTFAM is used as an experimental tool to model mitochondrial dysfunction in human colonoids and intestinal epithelial cells. By reducing TFAM levels, researchers can induce a state of mitochondrial deficiency characterized by lower mtDNA-encoded gene expression (e.g., Cox6A1, mt-CO1, ATP5A1) and reduced oxygen consumption rates. This model has been used to demonstrate that mitochondrial deficiency impairs crypt fissioning and mucosal repair in Inflammatory Bowel Disease (IBD), suggesting that therapeutic strategies to improve mitochondrial function could enhance ulcer healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shTFAM.